Collaborative and Other Relationships Collaborative and Other Relationships (Tables)

9 Months Ended

Sep. 30, 2018

Revenues from anti-CD20 therapeutic programs are summarized as follows:



	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
(In millions)	2018		2017		2018		2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	358.0	$	325.1	$	1,066.6	$	996.1
Other revenues from anti-CD20 therapeutic programs	153.7		81.4		378.7		148.1
Total revenues from anti-CD20 therapeutic programs	$	511.7	$	406.5	$	1,445.3	$	1,144.2

A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:



	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
(In millions)	2018		2017		2018		2017
Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat	$	64.9	$	38.3	$	176.0	$	105.0
Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income	$	32.5	$	19.2	$	88.0	$	52.5

A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:



	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
(In millions)	2018		2017		2018		2017
Total aducanumab development expense	$	64.8	$	73.3	$	204.8	$	202.2
Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income	$	55.1	$	73.3	$	183.6	$	202.2

Total aducanumab sales and marketing expense incurred by the collaboration	$	12.1	$	5.1	$	33.3	$	14.9
Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense our condensed consolidated statements of income	$	5.1	$	5.1	$	19.0	$	14.9